JNJ
Johnson & Johnson
$275.23
-3.20
(-1.15%)
Mkt Cap
663.28B
Volume
3,878,977
52W Range
173.33-281.07
Sector
Healthcare
Beta
0.23
EPS (TTM)
8.65 USD
P/E Ratio
31.82
Revenue (TTM)
97.93B USD
Rev Growth (5Y)
+2.3%
EPS Growth (5Y)
+11.5%
AlphaVal · Fair Value
What we estimate one share is worth
$154.42
Overvalued
strong signal
78.2% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B+
Stable Earnings Power
78.9 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.19B | 88.82B | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B | 81.58B | 76.45B | 71.89B | 70.07B | 74.33B |
| Net Income | 26.80B | 14.07B | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B | 15.41B | 16.32B |
| EPS | 11.03 | 5.84 | 13.88 | 6.83 | 7.93 | 5.59 | 5.74 | 5.75 | 0.48 | 6.08 | 5.57 | 5.86 |
| Free Cash Flow | 19.70B | 19.84B | 18.25B | 17.18B | 19.76B | 20.19B | 19.92B | 18.53B | 17.78B | 15.54B | 15.82B | 14.76B |
| FCF / Share | 8.11 | 8.24 | 7.20 | 6.58 | 7.52 | 7.67 | 7.57 | 6.96 | 6.63 | 5.74 | 5.74 | 5.30 |
| Operating CF | 24.53B | 24.27B | 22.79B | 21.19B | 23.41B | 23.54B | 23.42B | 22.20B | 21.06B | 18.77B | 19.28B | 18.47B |
| Total Assets | 199.21B | 180.10B | 167.56B | 187.38B | 182.02B | 174.89B | 157.73B | 152.95B | 157.30B | 141.21B | 133.41B | 130.36B |
| Total Debt | 47.93B | 36.63B | 29.33B | 39.64B | 33.75B | 35.27B | 27.70B | 30.48B | 34.58B | 27.13B | 19.86B | 18.76B |
| Cash & Equiv | 19.71B | 24.11B | 21.86B | 12.89B | 14.49B | 13.98B | 17.30B | 18.11B | 17.82B | 18.97B | 13.73B | 14.52B |
| Book Value | 81.54B | 71.49B | 68.77B | 76.80B | 74.02B | 63.28B | 59.47B | 59.75B | 60.16B | 70.42B | 71.15B | 69.75B |
| Return on Equity | 0.33 | 0.20 | 0.51 | 0.23 | 0.28 | 0.23 | 0.25 | 0.26 | 0.02 | 0.23 | 0.22 | 0.23 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.31B | 24.06B | 24.56B | 23.99B | 23.74B | 21.89B | 22.52B | 22.47B | 22.45B | 21.38B | 21.39B | 21.35B |
| Net Income | 5.53B | 5.24B | 5.12B | 5.15B | 5.54B | 11.00B | 3.43B | 2.69B | 4.69B | 3.25B | 4.05B | 26.03B |
| EPS | 2.27 | 2.14 | 2.10 | 2.14 | 2.29 | 4.57 | 1.43 | 1.12 | 1.95 | 1.35 | 1.68 | 10.32 |
| Free Cash Flow | 3.39B | 1.47B | 5.47B | 8.38B | 2.48B | 3.38B | 4.84B | 5.71B | 4.66B | 2.85B | 6.27B | 6.52B |
| FCF / Share | 1.39 | 0.60 | 2.25 | 3.45 | 1.03 | 1.40 | 2.01 | 2.37 | 1.93 | 1.18 | 2.61 | 2.59 |
| Operating CF | 4.71B | 2.51B | 7.31B | 9.17B | 3.88B | 4.17B | 6.98B | 7.99B | 5.63B | 3.66B | 7.86B | 7.49B |
| Total Assets | 201.06B | 200.89B | 199.21B | 192.82B | 193.39B | 193.67B | 180.10B | 178.29B | 181.09B | 171.97B | 167.56B | 166.06B |
| Total Debt | 49.04B | 54.99B | 47.93B | 45.80B | 50.76B | 52.25B | 36.63B | 35.75B | 41.49B | 33.63B | 29.33B | 29.92B |
| Cash & Equiv | 20.42B | 21.69B | 19.71B | 18.23B | 18.58B | 38.47B | 24.11B | 19.98B | 24.88B | 25.47B | 21.86B | 19.73B |
| Book Value | 84.97B | 81.19B | 81.54B | 79.28B | 78.47B | 78.11B | 71.49B | 70.16B | 71.54B | 70.02B | 68.77B | 71.23B |
| Return on Equity | 0.07 | 0.06 | 0.06 | 0.06 | 0.07 | 0.14 | 0.05 | 0.04 | 0.07 | 0.05 | 0.06 | 0.37 |
JNJ News
Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect.
Evolve Private Wealth LLC Has $7.96 Million Holdings in Johnson & Johnson $JNJ
GQG Partners LLC Sells 7,292,131 Shares of Johnson & Johnson $JNJ
Compass Financial Management LLC Makes New Investment in Johnson & Johnson $JNJ
Emerald Investment Advisers LLC Purchases 7,121 Shares of Johnson & Johnson $JNJ
Daiichi Life Insurance Co. Ltd. Acquires 8,767 Shares of Johnson & Johnson $JNJ
Clear Harbor Asset Management LLC Lowers Holdings in Johnson & Johnson $JNJ
Commerce Bank Increases Position in Johnson & Johnson $JNJ
Haverford Trust Co Sells 22,652 Shares of Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Shares Sold by Farringdon Capital Ltd.